NCT00477529 - ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer | Biotech Hunter

Enrollment

102

Participants

Timeline

Start Date

April 1, 2007

Primary Completion Date

June 2, 2011

Study Completion Date

June 2, 2011

Conditions

Hormone Refractory Prostate Cancer

Interventions

DRUG

ABI-008

nab-docetaxel

Trial Locations (4)

University of Michigan Comprehensive Cancer Center, Ann Arbor

Washington University School of Medicine, St Louis

Nebraska Methodist Hospital, Omaha

University of Texas M.D. Anderson Cancer Center, Houston